The Scottish Medicines Consortium (SMC), UK, has approved the supply of Emtricitabine / tenofovir disoproxil (Truvada) by the National Health Service (NHS) to prevent HIV in the nation.

Known as Pre Exposure Prophylaxis (PrEP), the drug will be a cost-effective treatment for sexually transmitted HIV-1 infection in adults who are at high risk of being infected.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The results from several studies are reported to confirm the ability of the drug to prevent new HIV infections.

SMC chairman Dr Alan MacDonald said: "Emtricitabine / tenofovir disproxil PrEP, when used together with safer sex practices may help to reduce the spread of HIV, which is an ongoing priority for the Scottish Government."

In December last year, NHS England has announced its plans to fund a clinical trial to evaluate PrEP in partnership with Public Health England.

"Emtricitabine / tenofovir disproxil PrEP, when used together with safer sex practices may help to reduce the spread of HIV, which is an ongoing priority for the Scottish Government."

Expected to be initiated in the early financial year 2017/18, the trial is expected to answer certain implementation questions by Public Health England, prior to the full release of the drug in England.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial will see an investment of £10m and a recruitment of approximately 10,000 subjects over a period of three years.

In addition to PrEP, SMC has approved four new drugs known as Trastuzumab emtansine (Kadcyla), ibrutinib (Imbruvica), Daclizumab (Zinbryta) and ixekizumab (Taltz).

Developed for the treatment of an advanced type of breast cancer known as HER2 positive metastatic breast cancer, Trastuzumab emtansine is expected to improve overall survival and quality of life for the patients.

While Ibrutinib was found to slow down the progression of chronic lymphocytic leukaemia (CLL), Daclizumab minimises the frequency of relapses and the progression of disability associated with multiple sclerosis (MS).

ixekizumab is approved to treat an inflammatory skin disorder called plaque psoriasis.